Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) - Episode 6

RATIONALE-306 Data on Tislelizumab in ESCC

,

Dr Yoon introduces tislelizumab, an anti-PD-1 immunotherapy regimen being investigated as a first-line ESCC treatment option in combination with chemotherapy, and discusses recent conference data from the RATIONALE-306 trial.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Trends in ESCC Incidence and Observations from Clinical Practice
    EP. 2: Approaches to Biomarker Testing for ESCC
    EP. 3: The Impact of Biomarker Results on Prognosis and Treatment Decision-Making
    EP. 4: First-Line Options for Advanced/Metastatic Disease
    EP. 5: Insights on ESCC First-Line Treatment Selection
    Now Viewing
    EP. 6: RATIONALE-306 Data on Tislelizumab in ESCC
    EP. 7: The Potential Impact of Tislelizumab on First-Line ESCC Treatment
    EP. 8: Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers
    EP. 9: A Look Towards the Future of ESCC
    x